Ulcerative Colitis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：360頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Ulcerative Colitis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Ulcerative Colitis - Pipeline Review, H1 2014’, provides an overview of the Ulcerative Colitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Ulcerative Colitis - Pipeline Review, H1 2014’, provides an overview of the Ulcerative Colitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis - Overview 12
Pipeline Products for Ulcerative Colitis - Comparative Analysis 13
Ulcerative Colitis - Therapeutics under Development by Companies 14
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 20
Ulcerative Colitis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Ulcerative Colitis - Products under Development by Companies 25
Ulcerative Colitis - Products under Investigation by Universities/Institutes 31
Ulcerative Colitis - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Amgen Inc. 34
Sanofi 35
AstraZeneca PLC 36
Athersys, Inc. 37
GlaxoSmithKline plc 38
Genentech, Inc. 39
MedImmune, LLC 40
Gilead Sciences, Inc. 41
Euroscreen S.A. 42
Takeda Pharmaceutical Company Limited 43
BioLineRx, Ltd. 44
Celltrion, Inc. 45
TiGenix NV 46
Biocon Limited 47
Pfizer Inc. 48
Sigma-Tau S.p.A. 49
Celgene Corporation 50
4SC AG 51
GW Pharmaceuticals plc 52
Harbor Therapeutics, Inc. 53
iCo Therapeutics Inc. 54
Kaken Pharmaceutical Co., Ltd. 55
Cosmo Pharmaceuticals S.p.A 56
Lexicon Pharmaceuticals, Inc. 57
LTT Bio-Pharma Co., Ltd. 58
Galapagos NV 59
InDex Pharmaceuticals AB 60
Am-Pharma B.V. 61
Farmacija d.o.o. Tuzla 62
Viropro Inc. 63
Tillotts Pharma AG 64
Coronado Biosciences, Inc. 65
GP Pharm, S.A. 66
Vascular Biogenics Ltd. 67
Indus Biotech Private Limited 68
Effimune SAS 69
Avaxia Biologics, Inc. 70
Enceladus Pharmaceuticals BV 71
Drais Pharmaceuticals, Inc. 72
Giuliani S.p.A. 73
Synergy Pharmaceuticals, Inc. 74
Medestea Research & Production S.p.A. 75
NasVax Ltd. 76
Stelic Institute & Co. 77
Antibe Therapeutics, Inc. 78
Dr. Falk Pharma GmbH 79
Flexion Therapeutics, Inc. 80
Zyngenia, Inc. 81
Receptos, Inc. 82
Altheus Therapeutics, Inc. 83
LIPID THERAPEUTICS GmbH 84
Atlantic Healthcare Limited 85
Sigmoid Pharma Ltd. 86
Advancell 87
Genor BioPharma Co., Ltd. 88
Aprogen, Inc. 89
ProtAb Ltd 90
Ajinomoto Pharmaceuticals Co., Ltd. 91
Qu Biologics Inc. 92
Oncobiologics, Inc. 93
Trino Therapeutics Ltd 94
Aniona ApS 95
ChironWells GmbH 96
Epirus Biopharmaceuticals, Inc. 97
AlphaMab Co., Ltd 98
INOXIA Lifesciences GmbH 99
Pharmapraxis 100
Ulcerative Colitis - Therapeutics Assessment 101
Assessment by Monotherapy Products 101
Assessment by Combination Products 102
Assessment by Target 103
Assessment by Mechanism of Action 108
Assessment by Route of Administration 114
Assessment by Molecule Type 117
Drug Profiles 120
budesonide - Drug Profile 120
vedolizumab - Drug Profile 123
budesonide - Drug Profile 125
mesalamine CR - Drug Profile 127
infliximab biosimilar - Drug Profile 128
infliximab biosimilar - Drug Profile 130
mesalamine ER - Drug Profile 131
tofacitinib - Drug Profile 133
DIMS-0150 - Drug Profile 137
vedolizumab - Drug Profile 139
infliximab - Drug Profile 141
budesonide ER - Drug Profile 143
levocarnitine propionate hydrochloride - Drug Profile 145
mesalamine - Drug Profile 146
infliximab biosimilar - Drug Profile 147
etrolizumab - Drug Profile 148
ASP-3291 - Drug Profile 150
tralokinumab - Drug Profile 151
eldelumab - Drug Profile 152
PF-05285401 - Drug Profile 154
GSK-1399686 - Drug Profile 157
telotristat etiprate - Drug Profile 158
budesonide - Drug Profile 160
budesonide - Drug Profile 163
vidofludimus - Drug Profile 165
PC-SOD - Drug Profile 169
VB-201 - Drug Profile 170
STNM-01 - Drug Profile 172
anrukinzumab - Drug Profile 173
LT-02 - Drug Profile 174
bertilimumab - Drug Profile 175
Prednisolone Sodium Phosphate Liposomal - Drug Profile 177
vatelizumab - Drug Profile 179
Low Molecular Weight Heparin - Drug Profile 180
TSO - Drug Profile 181
PF-00547659 - Drug Profile 183
sinecatechins - Drug Profile 185
AMG-181 - Drug Profile 186
CyCol - Drug Profile 188
(mesalamine + N-acetylcysteine) - Drug Profile 189
Natura-Alpha - Drug Profile 191
AJM-300 - Drug Profile 193
RPC-1063 - Drug Profile 195
Anti-CD3 Oral Immunotherapy - Drug Profile 197
GSK-2586184 - Drug Profile 199
BL-7040 - Drug Profile 201
GWP-42003 - Drug Profile 204
GLPG-0974 - Drug Profile 206
(metenkefalin + tridecactide) - Drug Profile 207
AJG-511 - Drug Profile 208
JNJ-54781532 - Drug Profile 209
HE-3286 - Drug Profile 210
apremilast - Drug Profile 212
AVX-470 - Drug Profile 214
Low Molecular Weight Heparin - Drug Profile 215
SP-333 - Drug Profile 216
infliximab biosimilar - Drug Profile 217
SAR-252067 - Drug Profile 218
GS-5745 - Drug Profile 219
KAG-308 - Drug Profile 220
GSK-3050002 - Drug Profile 221
infliximab biosimilar - Drug Profile 222
adalimumab biosimilar - Drug Profile 223
adalimumab biosimilar - Drug Profile 224
budesonide - Drug Profile 225
MD-707 - Drug Profile 227
Cx-602 - Drug Profile 228
GED-0507 - Drug Profile 229
Recombinant Human Alkaline Phosphatase - Drug Profile 230
(mesalamine + N-acetylcysteine) - Drug Profile 232
adalimumab biosimilar - Drug Profile 234
Leukothera - Drug Profile 235
ESN-282 - Drug Profile 236
ATB-429 - Drug Profile 237
adalimumab biosimilar - Drug Profile 239
ANs-42 - Drug Profile 240
QBECO SSI - Drug Profile 241
NS-17546 - Drug Profile 243
PH-46A - Drug Profile 244
Prozumab - Drug Profile 245
BLI-1006 - Drug Profile 246
IAC VITA - Drug Profile 247
adalimumab biosimilar - Drug Profile 249
AW/EPO-002 - Drug Profile 250
AW/EPOPD-02 - Drug Profile 251
AW/EPOPD-06 - Drug Profile 252
AW/EPOPD-01 - Drug Profile 253
AW/EPO-003 - Drug Profile 254
adalimumab biosimilar - Drug Profile 255
Anti Metallothioneins Antibodies - Drug Profile 256
GP-1200 - Drug Profile 257
PH-44 - Drug Profile 258
PH-5 - Drug Profile 259
Small Molecules to Inhibit IL-13 Receptor for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 260
Small Molecules Targeting IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 261
Bi-Specific Anti-TNFalpha/Ang2 Zybody - Drug Profile 262
VEDA-1209 - Drug Profile 263
RNPO Nanotherapy - Drug Profile 264
adalimumab biosimilar - Drug Profile 265
AB-0045 - Drug Profile 266
Alpha-Defensins - Drug Profile 267
INDUS-905 - Drug Profile 268
ONS-3015 - Drug Profile 269
Drug For Inflammatory Bowel Diseases - Drug Profile 270
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 271
infliximab biosimilar - Drug Profile 272
adalimumab biosimilar - Drug Profile 273
alicaforsen sodium - Drug Profile 274
adalimumab biosimilar - Drug Profile 275
infliximab biosmiliar - Drug Profile 276
SD-010 - Drug Profile 277
FX-003 - Drug Profile 278
adalimumab biosimilar - Drug Profile 279
Ulcerative Colitis - Recent Pipeline Updates 280
Ulcerative Colitis - Dormant Projects 341
Ulcerative Colitis - Discontinued Products 343
Ulcerative Colitis - Product Development Milestones 344
Featured News & Press Releases 344
Appendix 351
Methodology 351
Coverage 351
Secondary Research 351
Primary Research 351
Expert Panel Validation 351
Contact Us 352
Disclaimer 352
List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2014 20
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Development by Companies, H1 2014 (Contd..3) 26
Number of Products under Development by Companies, H1 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Development by Companies, H1 2014 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2014 40
Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2014 41
Ulcerative Colitis - Pipeline by Amgen Inc., H1 2014 42
Ulcerative Colitis - Pipeline by Sanofi, H1 2014 43
Ulcerative Colitis - Pipeline by AstraZeneca PLC, H1 2014 44
Ulcerative Colitis - Pipeline by Athersys, Inc., H1 2014 45
Ulcerative Colitis - Pipeline by GlaxoSmithKline plc, H1 2014 46
Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2014 47
Ulcerative Colitis - Pipeline by MedImmune, LLC, H1 2014 48
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2014 49
Ulcerative Colitis - Pipeline by Euroscreen S.A., H1 2014 50
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 51
Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H1 2014 52
Ulcerative Colitis - Pipeline by Celltrion, Inc., H1 2014 53
Ulcerative Colitis - Pipeline by TiGenix NV, H1 2014 54
Ulcerative Colitis - Pipeline by Biocon Limited, H1 2014 55
Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2014 56
Ulcerative Colitis - Pipeline by Sigma-Tau S.p.A., H1 2014 57
Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2014 58
Ulcerative Colitis - Pipeline by 4SC AG, H1 2014 59
Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H1 2014 60
Ulcerative Colitis - Pipeline by Harbor Therapeutics, Inc., H1 2014 61
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2014 62
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2014 63
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2014 64
Ulcerative Colitis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 65
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014 66
Ulcerative Colitis - Pipeline by Galapagos NV, H1 2014 67
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2014 68
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2014 69
Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 70
Ulcerative Colitis - Pipeline by Viropro Inc., H1 2014 71
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2014 72
Ulcerative Colitis - Pipeline by Coronado Biosciences, Inc., H1 2014 73
Ulcerative Colitis - Pipeline by GP Pharm, S.A., H1 2014 74
Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H1 2014 75
Ulcerative Colitis - Pipeline by Indus Biotech Private Limited, H1 2014 76
Ulcerative Colitis - Pipeline by Effimune SAS, H1 2014 77
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2014 78
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 79
Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H1 2014 80
Ulcerative Colitis - Pipeline by Giuliani S.p.A., H1 2014 81
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2014 82
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2014 83
Ulcerative Colitis - Pipeline by NasVax Ltd., H1 2014 84
Ulcerative Colitis - Pipeline by Stelic Institute & Co., H1 2014 85
Ulcerative Colitis - Pipeline by Antibe Therapeutics, Inc., H1 2014 86
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2014 87
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2014 88
Ulcerative Colitis - Pipeline by Zyngenia, Inc., H1 2014 89
Ulcerative Colitis - Pipeline by Receptos, Inc., H1 2014 90
Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H1 2014 91
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2014 92
Ulcerative Colitis - Pipeline by Atlantic Healthcare Limited, H1 2014 93
Ulcerative Colitis - Pipeline by Sigmoid Pharma Ltd., H1 2014 94
Ulcerative Colitis - Pipeline by Advancell, H1 2014 95
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2014 96
Ulcerative Colitis - Pipeline by Aprogen, Inc., H1 2014 97
Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2014 98
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 99
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2014 100
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2014 101
Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2014 102
Ulcerative Colitis - Pipeline by Aniona ApS, H1 2014 103
Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2014 104
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 105
Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H1 2014 106
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2014 107
Ulcerative Colitis - Pipeline by Pharmapraxis, H1 2014 108
Assessment by Monotherapy Products, H1 2014 109
Assessment by Combination Products, H1 2014 110
Number of Products by Stage and Target, H1 2014 113
Number of Products by Stage and Mechanism of Action, H1 2014 118
Number of Products by Stage and Route of Administration, H1 2014 124
Number of Products by Stage and Molecule Type, H1 2014 127
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2014 288
Ulcerative Colitis - Dormant Projects, H1 2014 349
Ulcerative Colitis - Discontinued Products, H1 2014 351
List of Figures
Number of Products under Development for Ulcerative Colitis, H1 2014 20
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 109
Assessment by Combination Products, H1 2014 110
Number of Products by Top 10 Target, H1 2014 111
Number of Products by Stage and Top 10 Target, H1 2014 112
Number of Products by Top 10 Mechanism of Action, H1 2014 116
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 117
Number of Products by Top 10 Route of Administration, H1 2014 122
Number of Products by Stage and Top 10 Route of Administration, H1 2014 123
Number of Products by Top 10 Molecule Type, H1 2014 125
Number of Products by Stage and Top 10 Molecule Type, H1 2014 126
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis - Overview 12
Pipeline Products for Ulcerative Colitis - Comparative Analysis 13
Ulcerative Colitis - Therapeutics under Development by Companies 14
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 20
Ulcerative Colitis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Ulcerative Colitis - Products under Development by Companies 25
Ulcerative Colitis - Products under Investigation by Universities/Institutes 31
Ulcerative Colitis - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Amgen Inc. 34
Sanofi 35
AstraZeneca PLC 36
Athersys, Inc. 37
GlaxoSmithKline plc 38
Genentech, Inc. 39
MedImmune, LLC 40
Gilead Sciences, Inc. 41
Euroscreen S.A. 42
Takeda Pharmaceutical Company Limited 43
BioLineRx, Ltd. 44
Celltrion, Inc. 45
TiGenix NV 46
Biocon Limited 47
Pfizer Inc. 48
Sigma-Tau S.p.A. 49
Celgene Corporation 50
4SC AG 51
GW Pharmaceuticals plc 52
Harbor Therapeutics, Inc. 53
iCo Therapeutics Inc. 54
Kaken Pharmaceutical Co., Ltd. 55
Cosmo Pharmaceuticals S.p.A 56
Lexicon Pharmaceuticals, Inc. 57
LTT Bio-Pharma Co., Ltd. 58
Galapagos NV 59
InDex Pharmaceuticals AB 60
Am-Pharma B.V. 61
Farmacija d.o.o. Tuzla 62
Viropro Inc. 63
Tillotts Pharma AG 64
Coronado Biosciences, Inc. 65
GP Pharm, S.A. 66
Vascular Biogenics Ltd. 67
Indus Biotech Private Limited 68
Effimune SAS 69
Avaxia Biologics, Inc. 70
Enceladus Pharmaceuticals BV 71
Drais Pharmaceuticals, Inc. 72
Giuliani S.p.A. 73
Synergy Pharmaceuticals, Inc. 74
Medestea Research & Production S.p.A. 75
NasVax Ltd. 76
Stelic Institute & Co. 77
Antibe Therapeutics, Inc. 78
Dr. Falk Pharma GmbH 79
Flexion Therapeutics, Inc. 80
Zyngenia, Inc. 81
Receptos, Inc. 82
Altheus Therapeutics, Inc. 83
LIPID THERAPEUTICS GmbH 84
Atlantic Healthcare Limited 85
Sigmoid Pharma Ltd. 86
Advancell 87
Genor BioPharma Co., Ltd. 88
Aprogen, Inc. 89
ProtAb Ltd 90
Ajinomoto Pharmaceuticals Co., Ltd. 91
Qu Biologics Inc. 92
Oncobiologics, Inc. 93
Trino Therapeutics Ltd 94
Aniona ApS 95
ChironWells GmbH 96
Epirus Biopharmaceuticals, Inc. 97
AlphaMab Co., Ltd 98
INOXIA Lifesciences GmbH 99
Pharmapraxis 100
Ulcerative Colitis - Therapeutics Assessment 101
Assessment by Monotherapy Products 101
Assessment by Combination Products 102
Assessment by Target 103
Assessment by Mechanism of Action 108
Assessment by Route of Administration 114
Assessment by Molecule Type 117
Drug Profiles 120
budesonide - Drug Profile 120
vedolizumab - Drug Profile 123
budesonide - Drug Profile 125
mesalamine CR - Drug Profile 127
infliximab biosimilar - Drug Profile 128
infliximab biosimilar - Drug Profile 130
mesalamine ER - Drug Profile 131
tofacitinib - Drug Profile 133
DIMS-0150 - Drug Profile 137
vedolizumab - Drug Profile 139
infliximab - Drug Profile 141
budesonide ER - Drug Profile 143
levocarnitine propionate hydrochloride - Drug Profile 145
mesalamine - Drug Profile 146
infliximab biosimilar - Drug Profile 147
etrolizumab - Drug Profile 148
ASP-3291 - Drug Profile 150
tralokinumab - Drug Profile 151
eldelumab - Drug Profile 152
PF-05285401 - Drug Profile 154
GSK-1399686 - Drug Profile 157
telotristat etiprate - Drug Profile 158
budesonide - Drug Profile 160
budesonide - Drug Profile 163
vidofludimus - Drug Profile 165
PC-SOD - Drug Profile 169
VB-201 - Drug Profile 170
STNM-01 - Drug Profile 172
anrukinzumab - Drug Profile 173
LT-02 - Drug Profile 174
bertilimumab - Drug Profile 175
Prednisolone Sodium Phosphate Liposomal - Drug Profile 177
vatelizumab - Drug Profile 179
Low Molecular Weight Heparin - Drug Profile 180
TSO - Drug Profile 181
PF-00547659 - Drug Profile 183
sinecatechins - Drug Profile 185
AMG-181 - Drug Profile 186
CyCol - Drug Profile 188
(mesalamine + N-acetylcysteine) - Drug Profile 189
Natura-Alpha - Drug Profile 191
AJM-300 - Drug Profile 193
RPC-1063 - Drug Profile 195
Anti-CD3 Oral Immunotherapy - Drug Profile 197
GSK-2586184 - Drug Profile 199
BL-7040 - Drug Profile 201
GWP-42003 - Drug Profile 204
GLPG-0974 - Drug Profile 206
(metenkefalin + tridecactide) - Drug Profile 207
AJG-511 - Drug Profile 208
JNJ-54781532 - Drug Profile 209
HE-3286 - Drug Profile 210
apremilast - Drug Profile 212
AVX-470 - Drug Profile 214
Low Molecular Weight Heparin - Drug Profile 215
SP-333 - Drug Profile 216
infliximab biosimilar - Drug Profile 217
SAR-252067 - Drug Profile 218
GS-5745 - Drug Profile 219
KAG-308 - Drug Profile 220
GSK-3050002 - Drug Profile 221
infliximab biosimilar - Drug Profile 222
adalimumab biosimilar - Drug Profile 223
adalimumab biosimilar - Drug Profile 224
budesonide - Drug Profile 225
MD-707 - Drug Profile 227
Cx-602 - Drug Profile 228
GED-0507 - Drug Profile 229
Recombinant Human Alkaline Phosphatase - Drug Profile 230
(mesalamine + N-acetylcysteine) - Drug Profile 232
adalimumab biosimilar - Drug Profile 234
Leukothera - Drug Profile 235
ESN-282 - Drug Profile 236
ATB-429 - Drug Profile 237
adalimumab biosimilar - Drug Profile 239
ANs-42 - Drug Profile 240
QBECO SSI - Drug Profile 241
NS-17546 - Drug Profile 243
PH-46A - Drug Profile 244
Prozumab - Drug Profile 245
BLI-1006 - Drug Profile 246
IAC VITA - Drug Profile 247
adalimumab biosimilar - Drug Profile 249
AW/EPO-002 - Drug Profile 250
AW/EPOPD-02 - Drug Profile 251
AW/EPOPD-06 - Drug Profile 252
AW/EPOPD-01 - Drug Profile 253
AW/EPO-003 - Drug Profile 254
adalimumab biosimilar - Drug Profile 255
Anti Metallothioneins Antibodies - Drug Profile 256
GP-1200 - Drug Profile 257
PH-44 - Drug Profile 258
PH-5 - Drug Profile 259
Small Molecules to Inhibit IL-13 Receptor for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 260
Small Molecules Targeting IL-13 for Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 261
Bi-Specific Anti-TNFalpha/Ang2 Zybody - Drug Profile 262
VEDA-1209 - Drug Profile 263
RNPO Nanotherapy - Drug Profile 264
adalimumab biosimilar - Drug Profile 265
AB-0045 - Drug Profile 266
Alpha-Defensins - Drug Profile 267
INDUS-905 - Drug Profile 268
ONS-3015 - Drug Profile 269
Drug For Inflammatory Bowel Diseases - Drug Profile 270
Tumor Necrosis Factor Receptor 25 Antagonists - Drug Profile 271
infliximab biosimilar - Drug Profile 272
adalimumab biosimilar - Drug Profile 273
alicaforsen sodium - Drug Profile 274
adalimumab biosimilar - Drug Profile 275
infliximab biosmiliar - Drug Profile 276
SD-010 - Drug Profile 277
FX-003 - Drug Profile 278
adalimumab biosimilar - Drug Profile 279
Ulcerative Colitis - Recent Pipeline Updates 280
Ulcerative Colitis - Dormant Projects 341
Ulcerative Colitis - Discontinued Products 343
Ulcerative Colitis - Product Development Milestones 344
Featured News & Press Releases 344
Appendix 351
Methodology 351
Coverage 351
Secondary Research 351
Primary Research 351
Expert Panel Validation 351
Contact Us 352
Disclaimer 352
List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2014 20
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Development by Companies, H1 2014 (Contd..3) 26
Number of Products under Development by Companies, H1 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Development by Companies, H1 2014 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2014 40
Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2014 41
Ulcerative Colitis - Pipeline by Amgen Inc., H1 2014 42
Ulcerative Colitis - Pipeline by Sanofi, H1 2014 43
Ulcerative Colitis - Pipeline by AstraZeneca PLC, H1 2014 44
Ulcerative Colitis - Pipeline by Athersys, Inc., H1 2014 45
Ulcerative Colitis - Pipeline by GlaxoSmithKline plc, H1 2014 46
Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2014 47
Ulcerative Colitis - Pipeline by MedImmune, LLC, H1 2014 48
Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2014 49
Ulcerative Colitis - Pipeline by Euroscreen S.A., H1 2014 50
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 51
Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H1 2014 52
Ulcerative Colitis - Pipeline by Celltrion, Inc., H1 2014 53
Ulcerative Colitis - Pipeline by TiGenix NV, H1 2014 54
Ulcerative Colitis - Pipeline by Biocon Limited, H1 2014 55
Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2014 56
Ulcerative Colitis - Pipeline by Sigma-Tau S.p.A., H1 2014 57
Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2014 58
Ulcerative Colitis - Pipeline by 4SC AG, H1 2014 59
Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H1 2014 60
Ulcerative Colitis - Pipeline by Harbor Therapeutics, Inc., H1 2014 61
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2014 62
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2014 63
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2014 64
Ulcerative Colitis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 65
Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014 66
Ulcerative Colitis - Pipeline by Galapagos NV, H1 2014 67
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2014 68
Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2014 69
Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H1 2014 70
Ulcerative Colitis - Pipeline by Viropro Inc., H1 2014 71
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2014 72
Ulcerative Colitis - Pipeline by Coronado Biosciences, Inc., H1 2014 73
Ulcerative Colitis - Pipeline by GP Pharm, S.A., H1 2014 74
Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H1 2014 75
Ulcerative Colitis - Pipeline by Indus Biotech Private Limited, H1 2014 76
Ulcerative Colitis - Pipeline by Effimune SAS, H1 2014 77
Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2014 78
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 79
Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H1 2014 80
Ulcerative Colitis - Pipeline by Giuliani S.p.A., H1 2014 81
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2014 82
Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2014 83
Ulcerative Colitis - Pipeline by NasVax Ltd., H1 2014 84
Ulcerative Colitis - Pipeline by Stelic Institute & Co., H1 2014 85
Ulcerative Colitis - Pipeline by Antibe Therapeutics, Inc., H1 2014 86
Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2014 87
Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2014 88
Ulcerative Colitis - Pipeline by Zyngenia, Inc., H1 2014 89
Ulcerative Colitis - Pipeline by Receptos, Inc., H1 2014 90
Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H1 2014 91
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2014 92
Ulcerative Colitis - Pipeline by Atlantic Healthcare Limited, H1 2014 93
Ulcerative Colitis - Pipeline by Sigmoid Pharma Ltd., H1 2014 94
Ulcerative Colitis - Pipeline by Advancell, H1 2014 95
Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2014 96
Ulcerative Colitis - Pipeline by Aprogen, Inc., H1 2014 97
Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2014 98
Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2014 99
Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2014 100
Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2014 101
Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2014 102
Ulcerative Colitis - Pipeline by Aniona ApS, H1 2014 103
Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2014 104
Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 105
Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H1 2014 106
Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2014 107
Ulcerative Colitis - Pipeline by Pharmapraxis, H1 2014 108
Assessment by Monotherapy Products, H1 2014 109
Assessment by Combination Products, H1 2014 110
Number of Products by Stage and Target, H1 2014 113
Number of Products by Stage and Mechanism of Action, H1 2014 118
Number of Products by Stage and Route of Administration, H1 2014 124
Number of Products by Stage and Molecule Type, H1 2014 127
Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2014 288
Ulcerative Colitis - Dormant Projects, H1 2014 349
Ulcerative Colitis - Discontinued Products, H1 2014 351
List of Figures
Number of Products under Development for Ulcerative Colitis, H1 2014 20
Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 109
Assessment by Combination Products, H1 2014 110
Number of Products by Top 10 Target, H1 2014 111
Number of Products by Stage and Top 10 Target, H1 2014 112
Number of Products by Top 10 Mechanism of Action, H1 2014 116
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 117
Number of Products by Top 10 Route of Administration, H1 2014 122
Number of Products by Stage and Top 10 Route of Administration, H1 2014 123
Number of Products by Top 10 Molecule Type, H1 2014 125
Number of Products by Stage and Top 10 Molecule Type, H1 2014 126
